论文部分内容阅读
目的探讨屈螺酮炔雌醇片治疗青春期功能失调性子宫出血(功血)的临床效果。方法对64例中度贫血青春期功血患者的临床资料进行回顾性分析,并将其分为屈螺酮组(采用屈螺酮炔雌醇治疗)和去氧孕烯组(采用去氧孕烯炔雌醇治疗),每组32例。比较两组患者的疗效和不良反应。结果第1个疗程停药后:屈螺酮组血红蛋白[(96.4±16.5)g/L]与治疗前[(74.3±10.0)g/L]比较,差异有统计学意义(P<0.05),但与去氧孕烯组[(96.0±10.2)g/L]比较,差异无统计学意义(P>0.05);屈螺酮组月经评分<100分率(82.7%,26/32)与去氧孕烯组(93.8%,30/32)比较,差异无统计学意义(P>0.05)。第3个疗程停药后:屈螺酮组点滴出血率(3.1%,1/32)与去氧孕烯组(9.4%,3/32)比较,差异有统计学意义(P<0.05);屈螺酮组体质指数[(25.4±2.4)kg/m2]与治疗前[(25.4±2.5)kg/m2]比较,差异无统计学意义(P>0.05)。屈螺酮组复发率(9.4%,3/32)与去氧孕烯组(12.9%,4/31)比较,差异无统计学意义(P>0.05)。两组均未见严重不良反应。结论屈螺酮炔雌醇片用于青春期妇女功血的止血、控制周期及减少月经量、控制体质量疗效肯定,患者依从性好。
Objective To investigate the clinical efficacy of drospirenone ethinyl estradiol in the treatment of adolescent dysfunctional uterine bleeding (dysfunctional uterine bleeding). Methods The clinical data of 64 cases of adolescent dysfunctional uterine bleeding were retrospectively analyzed and divided into drospirenone group (treated with drospirenone ethinyl estradiol) and desogestrel group (treated with desogestrel Ethinyl estradiol treatment), 32 cases in each group. The efficacy and adverse reactions of the two groups were compared. Results After the first course of treatment was discontinued, the hemoglobin in the drospirenone group was significantly lower than that in the pretreated group ([(96.4 ± 16.5) g / L vs [74.3 ± 10.0] g / L] But no significant difference was found between the group of drospirenone and deoxepane [(96.0 ± 10.2) g / L] (P> 0.05); the rate of drospirenone group was lower than 100 (82.7%, 26/32) Oxyethyne group (93.8%, 30/32), the difference was not statistically significant (P> 0.05). After the third course of treatment was discontinued, the bleeding rate of drospirenone group (3.1%, 1/32) was significantly lower than that of the group of desogestrel (9.4%, 3/32) (P <0.05). Drospirenone group body mass index [(25.4 ± 2.4) kg / m2] and before treatment [(25.4 ± 2.5) kg / m2], the difference was not statistically significant (P> 0.05). The recurrence rate of drospirenone group (9.4%, 3/32) and desogestrel group (12.9%, 4/31) showed no significant difference (P> 0.05). No serious adverse reactions were seen in both groups. Conclusion Drospirenone ethinyl estradiol tablet is used for hemostasis, period control and menstrual flow reduction in adolescent women. The control efficacy of body weight is good, and the patient compliance is good.